There is one clinical trial.
Evaluation of the efficacy and safety of TCM differential treatment of COVID-19 in Jiangsu Province based on the historical prospective multicenter cohort study.
Description: comparison of the time of relief / disappearance of three main symptoms of fever, cough and shortness of breathMeasure: The relief of main symptoms/ disappearance rate of time Time: 9day
Description: with reference to the "pneumonia chest X-ray absorption Evaluation scale" developed by Renyi Yin et al, the final absorption judgment will be used to evaluate the chest CT absorption of patients with pneumonia, which is divided into four levels according to the degree of absorption: complete absorption, majority absorption, partial absorption and no absorption.Measure: Chest CT absorption Time: 9day
Description: With reference to the "Therapeutic effect Standard for diagnosis and Syndrome of Traditional Chinese Medicine" and "guiding principles for Clinical Research of New drugs of traditional Chinese Medicine", the final evaluation was based on clinical remission.Measure: Evaluation standard of comprehensive curative effect Time: 9day
Description: the detection negative rate of nasopharyngeal swab, conjunctival sac secretion virus nucleic acid.Measure: Virus antigen negative conversion rate Time: 9day
Description: the number of severe and critical cases occurred after the start of intervention.Measure: The number of severe and critical conversion cases Time: 9day
Description: defined as complications during isolation and hospitalization due to pneumonia infected by novel coronavirus, including bacterial infection, aggravation of underlying diseases, etcMeasure: Incidence of complications Time: 9day
Description: According to the Traditional Chinese Medicine symptom score scale, the change of symptom score before and after treatment was observed.The highest score was 92 points, and the lowest was 23 points. The higher the score, the more severe the symptoms.Measure: Traditional Chinese Medicine Syndrome Score Time: 9day
Description: Changes in c-reactive protein.Measure: CRP changes Time: 9day
Description: Changes in erythrocyte sedimentation rate.Measure: ESR changes Time: 9day
Description: Changes in procalcitonin.Measure: PCTchanges Time: 9day
Description: Changes of CD4+ and CD8+Measure: The index of T cell subsets changed Time: 9day
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports